Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Other solid neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 78Fulvestrant 68Cyclophosphamide 66Carboplatin 49Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Cisplatin 20Radiotherapy 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Injections, Subcutaneous × Breast × Clear all
NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡